
Shares of gene-sequencing equipment maker Illumina ILMN.O fall 2.7% to $94.6
Bernstein analysts say Roche's ROG.S new gene sequencing device designed to decode diseases such as cancer, immune disorders and neurodegenerative diseases outperforms ILMN's devices
ROG unveiled the device on Thursday, featuring gene sequencing capabilities that provides detailed insights into genetics, genomics and cell biology
ILMN shares had closed down 5.6% on Thursday, following the news
Bernstein raises questions about the accuracy of the ROG device but said it could be a serious threat to ILMN in some applications
ILMN has fallen 24.8% in the past 12 months